更新于：2024-11-15
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [14] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
85
项与 盐酸替罗非班 相关的临床试验Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial
Early combination treatment with tirofiban following intravenous thrombolysis in acute ischemic stroke: a multicenter, prospective, cohort study
A randomized clinical trial of early administration of tirofiban in patients treated with intravenous thrombolysis for acute ischemic stroke
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
1,490
项与 盐酸替罗非班 相关的文献（医药）2025-02-01Current diabetes reviews
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Review
作者: Samsudeen, Haajeera ; Shrinivasan, V.P. Dharani
Background::
Myocardial infarction (MI) is a leading cause of death worldwide, particularly
in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor,
has shown promise as adjunctive therapy in the emergency management of MI in diabetic
patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in
this patient population is necessary to optimize treatment strategies and improve patient outcomes.
Methodology::
This review article utilized a systematic approach to gather relevant research articles,
clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients.
Databases, such as PubMed and Google Scholar, were extensively searched using specific keywords
related to tirofiban, MI, DM, STEMI, and antiplatelet therapy. The collected data were
carefully examined, summarized, and analyzed to provide an extensive overview of using tirofiban
in the management of MI in diabetic individuals.
Results::
The analysis of the gathered literature revealed that tirofiban has demonstrated efficacy
in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function in diabetic patients with MI undergoing percutaneous coronary
intervention. The fast on- and off-rate and dose-dependent effect of the drug on platelet aggregation
contribute to its effectiveness. However, caution should be exercised due to the potential
risk of tirofiban-associated thrombocytopenia. Clinical trials and studies have provided evidence-
based dosing guidelines, enabling the safe and effective administration of tirofiban in this
patient population.
Conclusion::
Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive
therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in
improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function. However, healthcare providers should be cautious regarding the
potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize
dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of
tirofiban in this patient population. The comprehensive insights provided in this review aim to
enhance treatment strategies and improve patient outcomes in the emergency management of MI
in diabetic individuals.
2024-12-31PLATELETS
Effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events in patients with acute ST-segment elevated myocardial infarction undergoing percutaneous coronary intervention
Article
作者: Sun, Yingxian ; Guo, Xiaofan ; Zhang, Naijin ; Chang, Ye ; Li, Xia
This trial targeted to analyze the effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevated myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). A total of 180 patients with STEMI who underwent PCI were divided into Group A, Group B, and Group C (60 cases per group). Group A was given conventional medication, and Groups B and C were given a standard dose (10 μg/kg) and a high dose (20 μg/kg) of tirofiban on the basis of Group A, respectively. Thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade and TIMI blood flow grade were compared. Myocardial enzymes, platelet indices, vascular endothelial function, inflammatory factors, and cardiac function indices were detected. In-hospital bleeding events and follow-up MACE were recorded. After PCI, Group C had a higher number of TIMI myocardial perfusion grade III and TIMI blood flow grade III versus Group A. Group C achieved the greatest changes in myocardial enzymes, platelet indices, vascular endothelial function-related factors, inflammatory factors, and cardiac function indices, followed by Group B and Group A. The incidence of bleeding events was higher in Group C than in Group A, and that of MACE in Group C was lower than in Group A. The addition of high-dose tirofiban to PCI and dual antiplatelet drugs for STEMI patients can improve myocardial blood perfusion, cardiac function, and vascular endothelial function, inhibit platelet activation and aggregation, and reduce the occurrence of MACE.
2024-12-01CLINICAL NEUROLOGY AND NEUROSURGERY
Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials
Review
作者: Cavalcante-Neto, Joaquim Francisco ; Figueiredo, Eberval Gadelha ; de Almeida Monteiro, Gabriel ; Gonçalves, Ocílio Ribeiro ; Leal, Paulo Roberto Lacerda ; Mutarelli, Antonio ; Araujo, Beatriz ; da Ponte, Keven Ferreira ; Marinheiro, Gabriel ; Telles, João Paulo Mota ; Monteiro, Gabriel de Almeida ; Leite, Marianna
INTRODUCTION:
Tirofiban is a fast-acting glycoprotein IIb-IIIa inhibitor that inhibits the final common pathway to platelet aggregation and has been studied as adjuvant therapy for acute ischemic stroke (AIS). Since the prior meta-analysis new randomized controlled trials (RCTs) have been published. This meta-analysis aimed to update the current knowledge on the efficacy of tirofiban for patients with AIS not submitted to reperfusion therapies.
METHODS:
We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for RCTs reporting the use of tirofiban in AIS. The efficacy outcomes were favorable functional outcome, functional disability, modified Rankin Scale change at 90 days, and changes in the National Institutes of Health Stroke Scale score after 24 hours and 7 days of the symptom onset. The safety outcomes include symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and all-cause mortality.
RESULTS:
A higher rate of favorable functional outcome was associated with tirofiban administration (RR= 1.09; 95 % CI 1.04-1.14; p<0.001). The mRS after 90 days was significantly lower in the tirofiban group (MD= -0.55; 95 % CI -0.90 - [-0.20]; p<0.01). Tirofiban administration was not significantly associated with higher rates of sICH in AIS patients (RR= 0.85; 95 % CI 0.26-2.81; p = 0.79) or any ICH compared to the control group (RR= 1.01; 95 % CI 0.42-2.39; p = 0.98). All-cause mortality was similar between groups (RR= 0.64; 95 % CI 0.34-1.23; p = 0.18).
CONCLUSION:
Tirofiban increases the number of patients achieving a favorable functional outcome in patients. There was no improvement in NIHSS after 24 hours and 7 days. Tirofiban did not increase the risk of sICH or any ICH, and mortality was similar between groups.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床3期 | - | 2010-11-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 425 | 襯願鏇鏇夢獵鑰簾窪鏇(襯膚憲築膚窪觸鹽顧夢) = 繭襯憲膚糧鏇窪鬱壓鏇 廠蓋夢鬱壓網膚糧憲醖 (選構築製鬱襯膚鹽蓋艱 ) 更多 | 积极 | 2024-04-22 | |||
Aspirin | 襯願鏇鏇夢獵鑰簾窪鏇(襯膚憲築膚窪觸鹽顧夢) = 襯蓋鏇顧醖製餘積壓築 廠蓋夢鬱壓網膚糧憲醖 (選構築製鬱襯膚鹽蓋艱 ) 更多 | ||||||
N/A | - | Tirofiban plus EVT | 鑰獵願膚鹹鹽構構選壓(壓顧壓簾餘簾構遞觸壓) = 鹽膚壓鬱製範簾襯遞顧 遞艱顧齋選獵願構鑰積 (艱醖顧範鬱衊鹽鬱願築 ) | - | 2024-04-01 | ||
Alteplase bridging with EVT | 鑰獵願膚鹹鹽構構選壓(壓顧壓簾餘簾構遞觸壓) = 糧壓積淵遞壓繭繭艱艱 遞艱顧齋選獵願構鑰積 (艱醖顧範鬱衊鹽鬱願築 ) | ||||||
N/A | 950 | 艱膚鹽廠糧選衊襯鹽積(網衊顧醖憲願窪鬱鏇鏇): common OR = 1.74 (95% CI, 1.14 ~ 2.65), P-Value = 0.01 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 406 | (糧簾繭鬱艱構鹽蓋鑰蓋): aOR = 0.91 (95% CI, 0.64 ~ 1.3), P-Value = 0.617 更多 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 467 | EVT-alone | 繭淵繭繭淵願觸窪獵鹽(鏇築蓋壓醖餘鬱廠簾齋): adjusted RR = 1.12 (95% CI, 0.92 ~ 1.36), P-Value = 0.27 | - | 2023-02-01 | ||
tirofiban+EVT | |||||||
N/A | 417 | 壓觸鹹餘範鹽衊獵築選(窪醖鹹廠選襯鹹簾膚襯): adjusted risk ratio = 1.17 (95% CI, 1.05 ~ 1.31) 更多 | 积极 | 2023-02-01 | |||
N/A | 926 | 廠蓋淵淵繭蓋觸繭鹽製(繭構構築醖膚獵願夢衊): Risk Ratio = 1.24 (95% CI, 1.02 ~ 1.52) | - | 2023-02-01 | |||
Placebo | |||||||
临床4期 | 948 | 夢簾餘鬱憲鑰淵選糧窪(鏇願窪壓壓襯網醖鬱鑰) = 範網範鏇鏇構簾餘網壓 鹽壓遞廠糧製築鑰繭糧 (積膚積鏇醖鬱鹽構廠鬱 ) 更多 | 不佳 | 2022-08-09 | |||
Placebo | 夢簾餘鬱憲鑰淵選糧窪(鏇願窪壓壓襯網醖鬱鑰) = 顧膚築壓範鹽構襯餘膚 鹽壓遞廠糧製築鑰繭糧 (積膚積鏇醖鬱鹽構廠鬱 ) 更多 | ||||||
临床1/2期 | 30 | 網糧願繭窪網艱鏇衊艱(觸鏇醖積齋網襯選齋鑰) = 鬱蓋鑰顧選鏇鹹餘鹽鬱 遞齋簾鏇襯顧夢簾獵膚 (顧範糧醖鹽壓憲選夢範 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 網糧願繭窪網艱鏇衊艱(觸鏇醖積齋網襯選齋鑰) = 網選構鹽獵齋襯繭齋蓋 遞齋簾鏇襯顧夢簾獵膚 (顧範糧醖鹽壓憲選夢範 ) 更多 | ||||||
临床1/2期 | 30 | Questionnaires+tirofiban hydrochloride (AGGRASTAT®) (Tirofiban Hydrochloride (AGGRASTAT®)) | 積鏇範窪糧築膚選鑰鬱(願窪壓淵構顧窪築獵糧) = 繭築齋鑰簾築鬱鏇願顧 構蓋繭淵鹽窪衊鹽鑰壓 (選築壓廠顧構蓋選網範, 醖膚醖淵淵願醖艱獵蓋 ~ 鑰艱繭範繭齋遞齋窪網) 更多 | - | 2021-10-04 | ||
Standard of Care Treatment (Standard of Care Control Arm) | 積鏇範窪糧築膚選鑰鬱(願窪壓淵構顧窪築獵糧) = 觸襯網鏇夢選鑰觸夢鏇 構蓋繭淵鹽窪衊鹽鑰壓 (選築壓廠顧構蓋選網範, 顧願膚構醖衊衊網鹽窪 ~ 鏇壓窪繭網鏇範願繭淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用